*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicit ...

TRENDING: The Next Big AI Concern Runs Through Main Street Today's Spotlight IBD's 12 Days of Holiday Deals Celebrate the holidays with big discounts on IBD's premium products every day from Dec. 13-24. Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with a team of top market analysts. Is the Santa Claus Rally Real? Something big may be coming to town—check out IBD's guide to the Santa Claus Rally. More News Oracle Stock Jumps On Reports TikTok Signed Deal T ...

Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect With Us On stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any speci ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or perfo ...

Advanced Buying Strategies Workshop Purchase IBD's pre-recorded Advanced Buying Strategies workshop for only $395. Get Market Insights on IBD Live Join IBD Live to watch and discuss the market action in real time with a team of top market analysts. Is the Santa Claus Rally Real? Something big may be coming to town—check out IBD's guide to the Santa Claus Rally. BREAKING: Tech Futures Skid As Oracle Dives Today's Spotlight 4/06/2025 A Relative Strength Rating upgrade for WD-40 shows improving technical perfo ...

Core Viewpoint - Janux Therapeutics experienced a significant stock decline following the release of updated test results for its prostate cancer treatment, JANX007, which analysts believe may be an overreaction [1][2]. Group 1: Treatment Efficacy - In a study involving patients with castration-resistant prostate cancer, 30% of the 27 evaluable patients responded to JANX007, a decrease from 50% in the previous year, although the earlier analysis was based on only eight patients [2][3]. - Among 89 patients receiving two doses of JANX007, 73% achieved a PSA50 response, indicating a 50% reduction in PSA levels, while 26% experienced a 90% drop in PSA levels [4]. - The median progression-free survival (PFS) was reported at 7.3 months, with those receiving a specific dose showing a PFS of 7.9 months, comparable to rival drugs from Amgen and Johnson & Johnson [5]. Group 2: Analyst Perspectives - William Blair analyst Matt Phipps expressed optimism about JANX007's potential to achieve a best-in-disease profile and significant sales, despite the small patient groups [3][7]. - Wedbush analyst Robert Driscoll reduced his price target for Janux stock from 76 to 45, citing changes in the expected timeline for JANX007, while maintaining an outperform rating [8]. Group 3: Stock Performance - Following the news, Janux shares fell over 47% to 17.62, marking the lowest point since February 2024 [3]. - Prior to the decline, Janux shares had increased nearly 63% from a low of 21.73 in late September to a high of 35.34 [9]. - The stock's Relative Strength Rating improved from 7 three months ago to 86, although the recent drop placed shares below their 50-day and 200-day moving averages [9].

About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The Wall Street Journal Barron's MarketWatch Dow Jones Smart Money Connect W ...

Group 1 - Nasdaq leads the market as stocks open higher, with gold and silver prices rising, benefiting mining and gold stocks [1] - Enova International (ENVA) and Ero Copper (ERO) reached record highs, identified by IBD's Screen Of The Day for their strong relative strength [1] - Ero Copper reported a significant 156% increase in profits last quarter, leading to a key rating upgrade and an improvement in its relative strength rating to 79 [4] Group 2 - Enova International achieved a composite rating improvement to 96, meeting over 80 relative strength rating benchmarks [4] - The stock market is showing multifaceted strength with new highs, raising questions about which sectors can outperform industry leaders [4]

Dow Jones Futures Rise As American Eagle, Marvell Jump On Earnings; Stock Market Nears Highs 8:45 AM ETThe stock market closed modestly higher, trending toward record highs. CrowdStrike, Marvell and American Eagle were earnings movers late. BREAKING: Futures Rise; Marvell, American Eagle Jump One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Marvell Technology (MRVL) stock now clears that threshold, with a jump from 75 to 86 Monday. Â Hone Your Stock-Picking Skills By ...